{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:28:46Z","timestamp":1787318926629,"version":"build-2736575974"},"reference-count":21,"publisher":"SAGE Publications","issue":"14","license":[{"start":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T00:00:00Z","timestamp":1629244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen Inc.","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cephalalgia"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Erenumab (erenumab-aooe in the US) effectively reduces monthly migraine days in episodic and chronic migraine. This traditional outcome does not capture the intensity of headache pain on days with migraine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This post hoc analysis of two pivotal randomized, placebo-controlled studies in patients with episodic migraine and chronic migraine examined the effect of erenumab 70 and 140\u2009mg on migraine pain. Cumulative monthly migraine pain intensity is the sum of the peak pain intensity scores (0\u2009=\u2009no migraine to 3\u2009=\u2009migraine day with severe pain) on migraine days. Change from baseline in cumulative monthly migraine pain and average monthly pain intensity was assessed over months 4 to 6 for episodic migraine and month 3 for chronic migraine; change in average monthly pain intensity was assessed among monthly migraine days responders\/non-responders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Efficacy analysis included 946 patients for the episodic migraine study and 656 patients for the chronic migraine study. Cumulative monthly migraine pain decreased significantly with erenumab versus placebo ( p\u2009&lt;\u20090.001, for episodic migraine and chronic migraine). In addition, monthly average migraine pain intensity decreased significantly with erenumab versus placebo for episodic migraine ( p\u2009&lt;\u20090.01); decreases were non-significant for chronic migraine. In comparison with placebo-treated patients, a greater proportion of erenumab-treated patients were pain intensity responders regardless of threshold used. Episodic migraine and chronic migraine patients with a \u226550% reduction in monthly migraine days (responders) had a greater reduction in monthly average pain intensity than non-responders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Erenumab reduced cumulative monthly migraine pain in episodic migraine and chronic migraine patients and significantly reduced monthly average migraine pain in episodic migraine, demonstrating treatment benefit beyond reduction in migraine frequency. Clinical Trial Registration: ClinicalTrials.gov, NCT02456740; ClinicalTrials.gov, NCT02066415<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03331024211028966","type":"journal-article","created":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T02:19:11Z","timestamp":1629339551000},"page":"1458-1466","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Reduction in migraine pain intensity in patients treated with erenumab: A post hoc analysis of two pivotal randomized studies"],"prefix":"10.1177","volume":"41","author":[{"given":"Richard B","family":"Lipton","sequence":"first","affiliation":[{"name":"The Saul R. Korey Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W","family":"Dodick","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Phoenix, AZ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kudrow","sequence":"additional","affiliation":[{"name":"California Medical Clinic for Headache, Santa Monica, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8527-0725","authenticated-orcid":false,"given":"Uwe","family":"Reuter","sequence":"additional","affiliation":[{"name":"Department of Neurology, Charit\u00e9 Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Tenenbaum","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG., Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Amgen Inc., Thousand Oaks, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8073-719X","authenticated-orcid":false,"given":"Gabriel Paiva da Silva","family":"Lima","sequence":"additional","affiliation":[{"name":"Amgen Inc., Thousand Oaks, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise E","family":"Chou","sequence":"additional","affiliation":[{"name":"Amgen Inc., Thousand Oaks, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel D","family":"Mikol","sequence":"additional","affiliation":[{"name":"Amgen Inc., Thousand Oaks, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,8,18]]},"reference":[{"key":"bibr1-03331024211028966","doi-asserted-by":"publisher","DOI":"10.1111\/head.12878"},{"key":"bibr2-03331024211028966","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000323925.29520.e7"},{"key":"bibr3-03331024211028966","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"bibr4-03331024211028966","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2009.02748.x"},{"key":"bibr5-03331024211028966","doi-asserted-by":"publisher","DOI":"10.1111\/head.13456"},{"key":"bibr6-03331024211028966","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.1999.00006.x"},{"key":"bibr7-03331024211028966","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.115.227793"},{"key":"bibr8-03331024211028966","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419888222"},{"key":"bibr9-03331024211028966","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705848"},{"key":"bibr10-03331024211028966","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30083-2"},{"key":"bibr11-03331024211028966","volume-title":"Package insert","year":"2019"},{"key":"bibr12-03331024211028966","volume-title":"Summary of product characteristics","author":"Aimovig (erenumab)","year":"2018"},{"key":"bibr13-03331024211028966","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418758283"},{"key":"bibr14-03331024211028966","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418759786"},{"key":"bibr15-03331024211028966","unstructured":"ClinicalTrials.gov. Comprehensive assessment of erenumab efficacy in subjects with high frequency episodic migraine with at least 1 previously failed preventive treatment: A global, double-blind, placebo-controlled phase 4 study. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04252742 (2020, accessed 13 July 2021)."},{"key":"bibr16-03331024211028966","unstructured":"Center for Drug Evaluation and Research. Guidance for industry analgesic indications: Developing drug and biological products (draft guidance). Report, Silver Spring, MD, February 2014, Food and Drug Administration."},{"key":"bibr17-03331024211028966","unstructured":"Center for Drug Evaluation and Research. Application Number: 761119Orig1s000: Clinical Reviews (Vyepti). Report, Silver Spring, MD, 21 February 2019. Food and Drug Administration."},{"key":"bibr18-03331024211028966","unstructured":"Center for Drug Evaluation and Research. Application Number: 211280Orig1s000: Summary Review (Lasmiditan). Report, Silver Spring, MD, 11 October 2018. Food and Drug Administration."},{"key":"bibr19-03331024211028966","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2020.10.002"},{"key":"bibr20-03331024211028966","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2020.10.003"},{"key":"bibr21-03331024211028966","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2020.08.003"}],"container-title":["Cephalalgia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024211028966","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03331024211028966","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024211028966","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:49:10Z","timestamp":1777387750000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03331024211028966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,18]]},"references-count":21,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1177\/03331024211028966"],"URL":"https:\/\/doi.org\/10.1177\/03331024211028966","relation":{},"ISSN":["0333-1024","1468-2982"],"issn-type":[{"value":"0333-1024","type":"print"},{"value":"1468-2982","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,18]]}}}